Literature DB >> 23414411

Virus-like particles produced in plants as potential vaccines.

Nunzia Scotti1, Edward P Rybicki.   

Abstract

Virus-like particles (VLPs) have been produced as candidate vaccines in plants virtually since the introduction of biofarming. Even today, VLPs remain the best candidates for safe, immunogenic, efficacious and inexpensive vaccines. Well-characterized human animal viruses such as HBV, HCV, HIV and HPV, rotaviruses, norovirus, foot and mouth disease viruses and even influenza virus proteins have all been successfully investigated for VLP formation. Proteins have been produced in transgenic plants and via transient expression techniques; simple structures, structures depending on more than one protein, naked and enveloped particles have all been made. There have been multiple proofs of concept, more than a few proofs of efficacy, and several products moved into human trials. This review will cover the history of VLP production in plants, and will explore a few examples in detail to illustrate the potential of such a mode of production for human and animal medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23414411     DOI: 10.1586/erv.12.147

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  29 in total

1.  Assembly and Purification of Polyomavirus-Like Particles from Plants.

Authors:  Emeline V B Catrice; Frank Sainsbury
Journal:  Mol Biotechnol       Date:  2015-10       Impact factor: 2.695

2.  Meeting report VLPNPV: Session 5: Plant based technology.

Authors:  Lydia R Meador; Tsafrir S Mor
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties.

Authors:  Chao Wang; Veronique Beiss; Nicole F Steinmetz
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

4.  Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1.

Authors:  Shi-Hua Xiang
Journal:  Curr HIV Res       Date:  2013-09       Impact factor: 1.581

Review 5.  Plant-based vaccines for animals and humans: recent advances in technology and clinical trials.

Authors:  Natsumi Takeyama; Hiroshi Kiyono; Yoshikazu Yuki
Journal:  Ther Adv Vaccines       Date:  2015-09

Review 6.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

7.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

8.  Early vaccine availability represents an important public health advance for the control of pandemic influenza.

Authors:  Amy L Greer
Journal:  BMC Res Notes       Date:  2015-05-08

9.  Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody.

Authors:  Jantipa Jobsri; Alex Allen; Deepa Rajagopal; Michael Shipton; Kostya Kanyuka; George P Lomonossoff; Christian Ottensmeier; Sandra S Diebold; Freda K Stevenson; Natalia Savelyeva
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

Review 10.  Plant-based vaccines against viruses.

Authors:  Edward P Rybicki
Journal:  Virol J       Date:  2014-12-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.